A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

TAMPA, Fla. (Dec. 19, 2025) — A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

The Decipher Prostate Metastatic test is now available for metastatic prostate cancer, covered by Medicare for all risk levels. It helps clinicians determine which patients may benefit from treatment, ...

If you or a loved one are navigating the journey of prostate cancer, you know that every decision weighs heavily. You’ve likely faced surgery or initial treatments, only to encounter the fear that ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the launch of its Decipher Prostate Metastatic Genomic Classifier ...

Published in Cell, the study is the first strong evidence that a gene expression test performed on routinely collected prostate tissue can help guide therapy choices for prostate cancer patients whose ...

Share on Pinterest Scientists are working on developing a urine test to detect prostate cancer. Anchalee Phanmaha/Getty Images Early detection of prostate cancer remains a major clinical challenge due ...

The study's testing accurately identified prostate cancer 91% of the time and accurately ruled out men without prostate cancer 84% of the time. A urine-based biomarker panel may be a promising, ...